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Clinical PerspectiveWhat Is New?It is not known whether there is an association between serum uric acid and various cardiovascular and neurovascular outcomes.Mendelian randomization is a statistical approach that uses genetic variants such as single‐nucleotide polymorphisms as genetic instruments to make causal inferences on the nature of an exposure‐outcome relationship.This study used the Mendelian randomization technique to investigate the effect of genetically determined uric acid levels on cardiovascular and neurovascular outcomes under investigation in clinical trials.What Are the Clinical Implications?We did not find evidence of any clinically relevant causal association between uric acid and coronary heart disease, myocardial infarction, systolic blood pressure, cognitive function, Alzheimer disease or any type of ischemic stroke.The protective role of urate lowering drugs on cardiovascular disease suggested by many observational studies and clinical trials might be attributable to urate independent mechanisms.

 {#jah34339-sec-0008}

Observational studies have shown a relationship between higher serum uric acid levels and increased risk of stroke, coronary heart disease (CHD), total cardiovascular events and incident hypertension.[1](#jah34339-bib-0001){ref-type="ref"}, [2](#jah34339-bib-0002){ref-type="ref"}, [3](#jah34339-bib-0003){ref-type="ref"}, [4](#jah34339-bib-0004){ref-type="ref"} There may also be a complicated relationship with dementia---hyperuricemia may accelerate cerebrovascular disease resulting in vascular dementia,[5](#jah34339-bib-0005){ref-type="ref"} but may be neuroprotective in Alzheimer or Parkinson dementia, because of its antioxidant properties.[6](#jah34339-bib-0006){ref-type="ref"} However, causality has not been confirmed and there is considerable potential for confounding. The Mendelian randomization (MR) approach can overcome some of the limitations of observational studies such as confounding or reverse causation to make causal inferences.[7](#jah34339-bib-0007){ref-type="ref"} MR uses genetic variants randomly allocated at conception that are not associated with environmental confounders, such as single‐nucleotide polymorphisms (SNPs), as instruments to study the effect of varying an exposure on risk of a particular outcome.[7](#jah34339-bib-0007){ref-type="ref"} SNPs associated with uric acid can therefore be used as proxies for phenotypic serum uric acid levels to produce valid causal estimates when the underlying requisite assumptions of MR are met.[8](#jah34339-bib-0008){ref-type="ref"}

Horizontal pleiotropy represents a violation of the requisite MR assumptions and occurs when the instruments are associated directly with the outcome independently of the exposure.[9](#jah34339-bib-0009){ref-type="ref"} MR analyses studying the effects of uric acid on cardiovascular disease and hypertension have previously been performed, with some supporting a causal association.[10](#jah34339-bib-0010){ref-type="ref"}, [11](#jah34339-bib-0011){ref-type="ref"}, [12](#jah34339-bib-0012){ref-type="ref"} In addition, a recent MR study did not find an association between serum uric acid levels and Alzheimer disease risk, but other dementia types or cognitive function were not investigated.[13](#jah34339-bib-0013){ref-type="ref"} Similarly, to our knowledge there is no published MR investigation of the role of uric acid on ischemic stroke and its subtypes.

Clinical trials of allopurinol, the most widely used uric acid lowering drug, are underway in the setting of cardiovascular disease and are exploring effects on blood pressure, cardiovascular event rate in patients with CHD (ALL‐HEART)[14](#jah34339-bib-0014){ref-type="ref"} and on cognitive and cardiovascular outcomes in patients with stroke (XILO‐FIST \[Xanthine oxidase inhibition for improvement of long‐term outcomes following ischaemic stroke and transient ischaemic attack\]).[15](#jah34339-bib-0015){ref-type="ref"} Numerous other small studies are in progress exploring surrogate outcomes. Allopurinol lowers serum uric acid in a dose dependent fashion, but also reduces the formation of reactive oxygen species and some of its vascular effects may be independent of uric acid reduction.[16](#jah34339-bib-0016){ref-type="ref"} These clinical trials will help inform on whether allopurinol improves outcomes, although interpretation of the mechanism of any improvement will be limited.

In this study, we performed MR analyses investigating the relationship between genetically determined serum uric acid levels and the range of cardiovascular and associated outcomes under study in trials (cognitive performance, Alzheimer disease, CHD, myocardial infarction \[MI\], systolic blood pressure \[SBP\], ischemic stroke and its subtypes \[large‐artery atherosclerotic stroke {LAS}, cardioembolic stroke, and stroke caused by small‐vessel disease {SVS}\]). Methods for dealing with potential violations of the modelling assumptions were incorporated, including a range of statistical sensitivity analyses performed to investigate the robustness of the findings**.**

Methods {#jah34339-sec-0009}
=======

All data used in this study come from GWAS (genome‐wide association study) meta‐analyses for which ethical approval and patient consent were previously obtained. The data used are available upon reasonable request from the corresponding author.

Genetic Association Estimates {#jah34339-sec-0010}
-----------------------------

We used 28 SNPs associated with serum uric acid concentration at genome‐wide significance (*P*\<5×10^−8^) as genetic instruments. These were identified from a GWAS meta‐analysis of 110 347 participants of European ancestry.[17](#jah34339-bib-0017){ref-type="ref"} All 28 SNPs were replicated, and overall explained 5.8% of the variability in uric acid levels. In the largest study of the GWAS meta‐analysis, the mean uric acid concentration was 6.0 mg/dL and the standard deviation (SD) was 1.5 mg/dL. The strength of each instrument was evaluated using F‐statistic values, which were in turn calculated based on R^2^, the proportion of phenotypic variance explained by each SNP.[18](#jah34339-bib-0018){ref-type="ref"}, [19](#jah34339-bib-0019){ref-type="ref"}

Genetic association estimates of SNP‐outcome relationships were extracted from different data sets. For cognitive ability, SNPs were derived from a GWAS meta‐analysis performed by the UK Biobank and Cognition Genomics Consortium (COGENT) on 257 841 participants of European origin.[20](#jah34339-bib-0020){ref-type="ref"} Cognitive function was measured using a test of verbal‐numerical reasoning in the UK Biobank, and neuropsychological assessments in COGENT study, further details for which are available in the original reporting studies.[21](#jah34339-bib-0021){ref-type="ref"}, [22](#jah34339-bib-0022){ref-type="ref"} Cognitive performance was standardized (mean=0 and SD=1). Genetic association estimates for Alzheimer disease were extracted from the discovery stage of the International Genomics of Alzheimer\'s Project (IGAP), a meta‐analysis of 4 GWASs with a total of 17 008 cases and 37 154 controls, all of European ancestry.[23](#jah34339-bib-0023){ref-type="ref"} The Coronary Artery Disease Genome Wide Replication and Meta‐Analysis (CARDIoGRAM) plus The Coronary Artery Disease (C4D) (CARDIoGRAMplusC4D) 1000 Genomes‐based GWAS meta‐analysis was used to derive the association estimates for CHD and MI.[24](#jah34339-bib-0024){ref-type="ref"} There were 60 801 CHD cases and 123 504 controls, with the majority of participants (77%) being of European ancestry. The CHD definition included MI (≈70% of the total number of cases), acute coronary syndrome and angina pectoris. For SBP, data on 473 891 European‐ancestry participants from the UK Biobank were used, with SBP estimates obtained from automated readings at baseline assessment, and having a mean value of 137.82 and an SD of 19.3 in the considered population.[25](#jah34339-bib-0025){ref-type="ref"} Finally, for ischemic stroke and its subtypes LAS, cardioembolic stroke, and SVS, genetic association estimates were derived from a multi‐ancestry GWAS performed by the MEGASTROKE Consortium, on 60 341 cases of any type of ischemic stroke (6688 of LAS; 9006 of cardioembolic stroke; 11 710 of SVS) and 454 450 controls.[26](#jah34339-bib-0026){ref-type="ref"} Table [1](#jah34339-tbl-0001){ref-type="table"} contains the information for all the data sets used in this study.

###### 

Characteristics of All Outcome Data Sets

  Outcome                                                 Consortium              Definition                                                                                                                                                                                                                                                                                             Total Population   Ethnicity       Cases (%)        Controls   References
  ------------------------------------------------------- ----------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------ --------------- ---------------- ---------- --------------------------------------------------------------------------
  Cognitive performance                                   UK Biobank and COGENT   Cognitive performance was assessed using a test of verbal‐numerical reasoning in UK Biobank and various neuropsychological tests in COGENT study                                                                                                                                                       257 841            European        ···              ···        Lee et al (2018)[20](#jah34339-bib-0020){ref-type="ref"}
  Alzheimer disease                                       IGAP(Stage 1)           WHO definition; the most common form of dementia. Dementia is a syndrome in which there is deterioration in memory, thinking, behavior and the ability to perform everyday activities                                                                                                                  54 162             European        17 008 (31.4%)   37 154     Lambert et al (2013)[23](#jah34339-bib-0023){ref-type="ref"}
  Coronary heart disease                                  CARDIoGRAMplusC4D       Coronary stenosis \>30%, documented angina, documented myocardial infarction                                                                                                                                                                                                                           184 305            77% European    60 801 (33.0%)   23 504     Nikpay et al (2015)[24](#jah34339-bib-0024){ref-type="ref"}
  Myocardial infarction                                   CARDIoGRAMplusC4D       Documented myocardial infarction; myocardial cell necrosis attributable to major and constant ischemia                                                                                                                                                                                                 54 162             77% European    42 560 (78.6%)   11 602     Nikpay et al (2015)[24](#jah34339-bib-0024){ref-type="ref"}
  Systolic blood pressure                                 UK Biobank              Electronically measured systolic blood pressure at baseline visit                                                                                                                                                                                                                                      473 891            White British   ···              ···        UK Biobank (Neale\'s lab) (2018)[25](#jah34339-bib-0025){ref-type="ref"}
  Ischemic stroke---any type                              MEGASTROKE              WHO definition; rapidly developing clinical signs of focal (or global) disturbance of cerebral function, with symptoms lasting ≥24 h or leading to death, with no apparent cause other than of vascular origin of a neurological deficit persisting \>24 h related to a vascular insult to the brain   514 791            Mixed           60 341 (11.7%)   454 450    Malik et al (2018)[26](#jah34339-bib-0026){ref-type="ref"}
  Ischemic stroke---cardioembolic stroke                  MEGASTROKE              A type of ischemic stroke attributable to emboli coming from heart                                                                                                                                                                                                                                     514 791            Mixed           9006 (1.7%)      505 785    Malik et al (2018)[26](#jah34339-bib-0026){ref-type="ref"}
  Ischemic stroke---large‐artery atherosclerotic stroke   MEGASTROKE              A type of ischemic stroke attributable to atherosclerosis of major intracranial arteries                                                                                                                                                                                                               514 791            Mixed           6688 (1.3%)      508 103    Malik et al (2018)[26](#jah34339-bib-0026){ref-type="ref"}
  Ischemic stroke---small‐vessel disease stroke           MEGASTROKE              A type of ischemic stroke attributable to pathological processes of small arteries, arterioles, venules, and capillaries of the brain                                                                                                                                                                  514 791            Mixed           11 710 (2.3%)    503 081    Malik et al (2018)[26](#jah34339-bib-0026){ref-type="ref"}

COGENT indicates Cognition Genomics Consortium; IGAP, International Genomics of Alzheimer Project; WHO, World Health Organization.
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Mendelian Randomization Power Calculation {#jah34339-sec-0011}
-----------------------------------------

Information on the available sample size and the percentage of phenotypic variance explained by the instruments was used to perform power calculations for conventional MR analyses using the mRnd power calculator (available at <http://cnsgenomics.com/shiny/mRnd/>).[27](#jah34339-bib-0027){ref-type="ref"} The smallest effect of uric acid (on all outcomes separately) required to achieve at least 80% statistical power given the sample size and percentage of phenotypic variance explained was calculated for the main analysis.

Mendelian Randomization Analyses and Investigation of Pleiotropy {#jah34339-sec-0012}
----------------------------------------------------------------

For inverse‐variance weighted (IVW) ratio method MR, we generated MR estimates for each SNP using the Wald estimator (ratio of SNP‐outcome estimate over SNP‐exposure estimate), with standard errors calculated using the Delta method to account for possible measurement error in both the exposure and outcome association estimates.[28](#jah34339-bib-0028){ref-type="ref"}, [29](#jah34339-bib-0029){ref-type="ref"} In the main analysis, the final effect estimate for each outcome was derived by pooling all MR estimates using the fixed‐effects IVW method.[30](#jah34339-bib-0030){ref-type="ref"} As this method assumes the absence of any horizontal pleiotropic effects of the genetic instruments on the considered outcome through pathways independent of the exposure (which in this case is serum uric acid) and is vulnerable to bias if this assumption does not hold, further MR methods that have less stringent assumptions on horizontal pleiotropy were therefore performed in sensitivity analyses. We estimated the intercept and slope of MR‐Egger regression, which represent the average horizontal pleiotropy and a pleiotropy‐adjusted MR estimate, respectively.[31](#jah34339-bib-0031){ref-type="ref"} An intercept value for this regression that does not include the null (*P*\<0.05) was considered indicative of horizontal pleiotropy.[31](#jah34339-bib-0031){ref-type="ref"} MR‐Egger makes the assumption that the strength of the instruments is not correlated to any pleiotropic effect that they have.[31](#jah34339-bib-0031){ref-type="ref"} Additionally, the weighted median estimator was performed.[32](#jah34339-bib-0032){ref-type="ref"} This is the weighted median effect of all the MR estimates produced by individual instruments, with weights equal to the inverse of the standard error.[32](#jah34339-bib-0032){ref-type="ref"} It is valid when more than half the information from the analysis comes from valid instruments.[32](#jah34339-bib-0032){ref-type="ref"} Finally, the Mendelian Randomization Pleiotropy Residual Sum and Outlier (MR‐PRESSO) method was performed, which excludes outliers determined by the square of residual errors from the SNP‐outcome against SNP‐exposure regression to calculate an outlier‐free effect estimate.[33](#jah34339-bib-0033){ref-type="ref"}

Increased body mass index (BMI) has been causally associated with higher levels of serum uric acid in a recent MR study by Palmer et al.[11](#jah34339-bib-0011){ref-type="ref"} To reduce any possible genetic confounding related to associations of the uric acid instruments with BMI, we adjusted for this using conventional regression‐based multivariable MR.[34](#jah34339-bib-0034){ref-type="ref"} Multivariable MR is a linear regression‐based method with \>1 explanatory variable.[34](#jah34339-bib-0034){ref-type="ref"} The genetic association estimates for BMI were derived from a GWAS meta‐analysis of the Genetic Investigation of Anthropometric Traits (GIANT) Consortium and UK Biobank, including ≈700 000 European‐ancestry participants.[35](#jah34339-bib-0035){ref-type="ref"}

An additional sensitivity analysis to deal with any potential horizontal pleiotropy was performed. We examined whether the 28 SNPs were associated with any traits other than uric acid levels, using the PhenoScanner online data set of publicly available GWAS results (<http://www.phenoscanner.medschl.cam.ac.uk/phenoscanner>, accessed February 1, 2019), identifying associations that were genome‐wide significant (*P*\<5×10^−8^), and also considering proxy SNPs (linkage disequilibrium *r* ^2^\>0.8).[36](#jah34339-bib-0036){ref-type="ref"} The whole analysis was then repeated using only the SNPs that were exclusively associated with uric acid and/or gout. For the considered 9 outcomes, we accounted for multiple testing in the main analysis using a Bonferroni correction.

We used R software (version 3.5.1) and the MendelianRandomization[37](#jah34339-bib-0037){ref-type="ref"} and MRPRESSO[33](#jah34339-bib-0033){ref-type="ref"} software packages to perform analyses.

Results {#jah34339-sec-0013}
=======

All 28 SNPs had F‐statistic values \>10, suggesting that they were unlikely to introduce marked weak instrument bias into the MR analyses.[18](#jah34339-bib-0018){ref-type="ref"} Table [S1](#jah34339-sup-0001){ref-type="supplementary-material"} contains the individual association estimates for uric acid and F‐statistic values of each instrument SNP. Investigating potentially pleiotropic associations identified that only 7 out of the 28 instrument SNPs were exclusively associated with either uric acid levels and/or gout (Table [S2](#jah34339-sup-0001){ref-type="supplementary-material"}). Power calculations for the conventional IVW MR analyses using the 28 SNPs indicated \>80% statistical power to detect an odds ratio (OR) \<0.97 or \>1.04 per 1 mg/dL increase in uric acid for the urate‐CHD/MI relationships and a beta estimate smaller or \>0.096 per 1 mg/dL increase in uric acid for the urate‐SBP relationship. Similar power calculations were found for the MR analysis using the 7 SNPs specific to urate/gout. Tables [S3 and S4](#jah34339-sup-0001){ref-type="supplementary-material"} contain the power calculations for all outcomes for the 28 SNPs and 7 SNPs analyses, respectively. All results in this study are reported per 1 mg/dL increase in genetically determined uric acid.

Cognition and Alzheimer Disease {#jah34339-sec-0014}
-------------------------------

The results for uric acid and cognition are shown in Table [2](#jah34339-tbl-0002){ref-type="table"}. All analyses found an inverse relationship between serum uric acid level and cognitive performance. However, only the effect estimates from the weighted median method had a significant effect after adjusting for multiple testing using the Bonferroni correction (*P*\<0.005) (weighted median estimate for the 7 only‐urate associated SNPs: β −0.03; 95% CI −0.05--−0.01; *P*=3.77×10^−04^).[38](#jah34339-bib-0038){ref-type="ref"} The intercept of the MR‐Egger regression did not suggest the presence of directional pleiotropy (*P*=0.72). Results were consistent between all 28 and 7 SNPs.

###### 

Results From All MR Analyses for the Association of Uric Acid With Cognitive Performance and Alzheimer Disease

  Uric Acid on Cognition                                        β (95% CI)             *P* Value
  ------------------------------------------------------------- ---------------------- --------------
  Analysis with 28 SNPs                                                                
  Fixed‐effects IVW                                             −0.02 (−0.04--0.01)    0.16
  Weighted median                                               −0.03 (−0.05--−0.01)   1.00×10^−03^
  MR‐Egger                                                      −0.02 (−0.06--0.01)    0.22
  MR‐PRESSO (outliers corrected; 3 outliers)                    −0.02 (−0.04--−0.01)   0.02
  MR‐PRESSO (raw)                                               −0.02 (−0.04--0.01)    0.17
  MVMR adjusting for BMI                                        −0.02 (−0.04--0.01)    0.19
  Analysis with 7 SNPs[a](#jah34339-note-0006){ref-type="fn"}                          
  Fixed‐effects IVW                                             −0.03 (−0.06--0.00)    0.08
  Weighted median                                               −0.03 (−0.05--−0.01)   3.77×10^−04^
  MR‐Egger                                                      −0.03 (−0.07--0.02)    0.27
  MR‐PRESSO (raw; 0 outliers)                                   −0.03 (−0.07--0.00)    0.09

  Uric Acid on Alzheimer                                        OR (95% CI)         *P* Value
  ------------------------------------------------------------- ------------------- -----------
  Analysis with 28 SNPs                                                             
  Fixed‐effects IVW                                             1.03 (0.96--1.10)   0.47
  Weighted median                                               1.04 (0.95--1.14)   0.42
  MR‐Egger                                                      1.08 (0.98--1.20)   0.12
  MR‐PRESSO (raw; 0 outliers)                                   1.03 (0.96--1.10)   0.49
  MVMR adjusting for BMI                                        1.03 (0.96--1.11)   0.35
  Analysis with 7 SNPs[a](#jah34339-note-0006){ref-type="fn"}                       
  Fixed‐effects IVW                                             1.05 (0.93--1.17)   0.48
  Weighted median                                               1.05 (0.95--1.15)   0.31
  MR‐Egger                                                      1.06 (0.90--1.25)   0.48
  MR‐PRESSO (raw; 0 outliers)                                   1.04 (0.93--1.17)   0.49

BMI indicates body mass index; IVW, inverse variance weighted; MR‐PRESSO, Mendelian Randomization Pleiotropy Residual Sum and Outlier; MR, Mendelian randomization; MVMR, multivariable Mendelian randomization analysis; SNP, single‐nucleotide polymorphisms.

The 7 non‐pleiotropic SNPs that are associated with only uric acid or/and gout.

John Wiley & Sons, Ltd

Regarding Alzheimer disease, there was no demonstrable relationship with uric acid in any analysis (IVW method for the 7 SNPs analysis: OR 1.05; 95% CI 0.93--1.17; *P*=0.48). In addition, no horizontal pleiotropy was suggested by the MR‐Egger test (*P*=0.13). Detailed results can be found in Table [2](#jah34339-tbl-0002){ref-type="table"}.

Coronary Heart Disease and Myocardial Infarction {#jah34339-sec-0015}
------------------------------------------------

There was an apparent effect of uric acid on CHD in outlier‐corrected MR‐PRESSO (OR 1.07; 95% CI 1.03--1.12; *P*=2.99×10^−3^), but not in any other method or in analyses restricted to the 7 SNPs specific for urate (Table [3](#jah34339-tbl-0003){ref-type="table"}). The MR‐Egger test did not provide evidence of horizontal pleiotropy (*P*=0.06). Similar results were found for MI (Table [3](#jah34339-tbl-0003){ref-type="table"}).

###### 

Results From All MR Analyses for the Association of Uric Acid With Coronary Heart Disease, Myocardial Infarction, and Systolic Blood Pressure

  Uric Acid on CHD                                              OR (95% CI)         *P* Value
  ------------------------------------------------------------- ------------------- --------------
  Analysis with 28 SNPs                                                             
  Fixed‐effects IVW                                             1.08 (1.02--1.14)   0.01
  Weighted median                                               1.05 (0.99--1.11)   0.10
  MR‐Egger                                                      1.02 (0.94--1.12)   0.63
  MR‐PRESSO (outlier corrected; 1 outlier)                      1.07 (1.03--1.12)   2.99×10^−03^
  MR‐PRESSO (raw)                                               1.08 (1.02--1.16)   0.02
  MVMR adjusting for BMI                                        1.07 (1.01--1.14)   0.04
  Analysis with 7 SNPs[a](#jah34339-note-0008){ref-type="fn"}                       
  Fixed‐effects IVW                                             1.04 (0.97--1.11)   0.29
  Weighted median                                               1.03 (0.97--1.09)   0.29
  MR‐Egger                                                      1.03 (0.95--1.11)   0.58
  MR‐PRESSO (raw; 0 outliers)                                   1.04 (0.97--1.11)   0.29

  Uric Acid on MI                                               OR (95% CI)         *P* Value
  ------------------------------------------------------------- ------------------- --------------
  Analysis with 28 SNPs                                                             
  Fixed‐effects IVW                                             1.09 (1.02--1.16)   0.02
  Weighted median                                               1.06 (0.99--1.12)   0.08
  MR‐Egger                                                      1.01 (0.92--1.12)   0.80
  MR‐PRESSO (outlier corrected; 1 outlier)                      1.08 (1.03--1.14)   4.41×10^−03^
  MR‐PRESSO (raw)                                               1.10 (1.01--1.18)   0.03
  MVMR adjusting for BMI                                        1.08 (1.00--1.17)   0.05
  Analysis with 7 SNPs[a](#jah34339-note-0008){ref-type="fn"}                       
  Fixed‐effects IVW                                             1.04 (0.97--1.12)   0.28
  Weighted median                                               1.04 (0.98--1.11)   0.22
  MR‐Egger                                                      1.03 (0.93--1.14)   0.54
  MR‐PRESSO (raw; 0 outliers)                                   1.04 (0.97--1.12)   0.28

  Uric Acid on SBP                                              β (95% CI)              *P* Value
  ------------------------------------------------------------- ----------------------- -----------
  Analysis with 28 SNPs                                                                 
  Fixed‐effects IVW                                             0.47 (−0.02 to 0.95)    0.07
  Weighted median                                               0.23 (−0.07 to 0.53)    0.13
  MR‐Egger                                                      −0.25 (−0.97 to 0.47)   0.49
  MR‐PRESSO (outlier corrected; 4 outliers)                     0.58 (0.19--0.97)       0.01
  MR‐PRESSO (raw)                                               0.57 (−0.02 to 1.16)    0.07
  MVMR adjusting for BMI                                        0.56 (−0.05 to 1.17)    0.08
  Analysis with 7 SNPs[a](#jah34339-note-0008){ref-type="fn"}                           
  Fixed‐effects IVW                                             0.34 (−0.18 to 0.86)    0.25
  Weighted median                                               0.21 (−0.09 to 0.51)    0.15
  MR‐Egger                                                      −0.12 (−0.53 to 0.30)   0.59
  MR‐PRESSO (outliers corrected; 1 outlier)                     0.31 (−0.19 to 0.80)    0.28
  MR‐PRESSO (raw)                                               0.36 (−0.19 to 0.90)    0.25

BMI indicates body mass index; CHD, coronary heart disease; IVW, inverse variance weighted; MR‐PRESSO, Mendelian Randomization Pleiotropy Residual Sum and Outlier; MI, myocardial infarction; MR, Mendelian randomization; MVMR, multivariable Mendelian randomization analysis; SBP, systolic blood pressure.

The 7 non‐pleiotropic SNPs that are associated with only uric acid or/and gout.
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Systolic Blood Pressure {#jah34339-sec-0016}
-----------------------

In the main analysis using the 28 SNPs, 1 mg/dL increase in uric acid was associated with 0.47 mm Hg increase in SBP (IVW method: 95% CI −0.02--0.95; *P*=0.07). There was a suggestive association when performing the outlier corrected MR‐PRESSO method with all 28 SNPs, but this was not statistically significant after Bonferroni correction (MR‐PRESSO method; β 0.58; 95% CI 0.19--0.97; *P*=0.01) (Table [3](#jah34339-tbl-0003){ref-type="table"}). In addition, the MR‐Egger test suggested the presence of horizontal pleiotropy when considering all 28 SNPs (*P*=2×10^−3^).

Stroke {#jah34339-sec-0017}
------

The effect estimates for ischemic stroke and its subtypes were consistent throughout all analysis methods and were not suggestive of an association between uric acid and ischemic stroke or its subtypes (Table [4](#jah34339-tbl-0004){ref-type="table"}). The OR for the effect of genetically determined uric acid on any type of ischemic stroke when using the IVW method in the 28 SNPs analysis was 1.00 (95% CI 0.94--1.06; *P*=0.99) and was consistent after adjusting for BMI in multivariable Mendelian randomization (OR 0.99; 95% CI 0.92--1.07; *P*=0.89) or after using the 7 SNPs associated with only uric acid/gout (IVW: OR 0.96; 95% CI 0.91--1.02; *P*=0.20). The MR‐Egger intercepts of all stroke analyses were found to be close to 0, indicating the absence of horizontal pleiotropy.

###### 

Results From All MR Analyses for the Association of Uric Acid With Ischemic Stroke and its Subtypes

  Uric Acid on Ischemic Stroke                                  OR (95% CI)         *P* Value
  ------------------------------------------------------------- ------------------- -----------
  Analysis with 28 SNPs                                                             
  Fixed‐effects IVW                                             1.00 (0.94--1.06)   0.99
  Weighted median                                               0.98 (0.93--1.03)   0.42
  MR‐Egger                                                      0.95 (0.85--1.05)   0.31
  MR‐PRESSO (outlier corrected; 1 outlier)                      1.00 (0.95--1.05)   0.87
  MR‐PRESSO (raw)                                               1.00 (0.94--1.08)   0.86
  MVMR adjusting for BMI                                        0.99 (0.92--1.07)   0.89
  Analysis with 7 SNPs[a](#jah34339-note-0010){ref-type="fn"}                       
  Fixed‐effects IVW                                             0.96 (0.91--1.02)   0.20
  Weighted median                                               0.97 (0.92--1.03)   0.33
  MR‐Egger                                                      0.99 (0.93--1.06)   0.82
  MR‐PRESSO (raw; 0 outliers)                                   0.96 (0.91--1.02)   0.20

  Uric Acid on CES                                              OR (95% CI)         *P* Value
  ------------------------------------------------------------- ------------------- -----------
  Analysis with 28 SNP                                                              
  Fixed‐effects IVW                                             0.97 (0.89--1.05)   0.44
  Weighted median                                               0.95 (0.86--1.05)   0.32
  MR‐Egger                                                      0.92 (0.82--1.04)   0.20
  MR‐PRESSO (raw; 0 outliers)                                   0.97 (0.89--1.06)   0.49
  MVMR adjusting for BMI                                        0.97 (0.89--1.06)   0.50
  Analysis with 7 SNPs[a](#jah34339-note-0010){ref-type="fn"}                       
  Fixed‐effects IVW                                             0.93 (0.87--1.00)   0.08
  Weighted median                                               0.95 (0.85--1.06)   0.33
  MR‐Egger                                                      0.97 (0.85--1.10)   0.60
  MR‐PRESSO (raw; 0 outliers)                                   0.93 (0.87--1.00)   0.08

  LAS                                                           OR (95% CI)         *P* Value
  ------------------------------------------------------------- ------------------- -----------
  Analysis with 28 SNPs                                                             
  Fixed‐effects IVW                                             1.01 (0.88--1.15)   0.94
  Weighted median                                               0.94 (0.83--1.07)   0.36
  MR‐Egger                                                      0.89 (0.74--1.08)   0.24
  MR‐PRESSO (outliers corrected; 1 outlier)                     1.00 (0.88--1.13)   0.98
  MR‐PRESSO (raw)                                               1.01 (0.88--1.16)   0.87
  MVMR adjusting for BMI                                        1.00 (0.86--1.15)   0.98
  Analysis with 7 SNPs[a](#jah34339-note-0010){ref-type="fn"}                       
  Fixed‐effects IVW                                             0.92 (0.84--1.01)   0.13
  Weighted median                                               0.93 (0.81--1.06)   0.27
  MR‐Egger                                                      0.93 (0.79--1.10)   0.41
  MR‐PRESSO (raw; 0 outliers)                                   0.92 (0.84--1.01)   0.13

  SVS                                                           OR (95% CI)         *P* Value
  ------------------------------------------------------------- ------------------- -----------
  Analysis with 28 SNPs                                                             
  Fixed‐effects IVW                                             1.04 (0.92--1.16)   0.55
  Weighted median                                               1.05 (0.94--1.17)   0.41
  MR‐Egger                                                      1.08 (0.90--1.28)   0.42
  MR‐PRESSO (outliers corrected; 1 outlier)                     1.03 (0.93--1.13)   0.62
  MR‐PRESSO (raw)                                               1.04 (0.92--1.17)   0.54
  MVMR adjusting for BMI                                        1.02 (0.90--1.15)   0.79
  Analysis with 7 SNPs[a](#jah34339-note-0010){ref-type="fn"}                       
  Fixed‐effects IVW                                             1.02 (0.93--1.12)   0.71
  Weighted median                                               1.04 (0.92--1.17)   0.56
  MR‐Egger                                                      1.09 (0.94--1.26)   0.27
  MR‐PRESSO (raw; 0 outliers)                                   1.02 (0.93--1.12)   0.72

BMI indicates body mass index; CES, cardioembolic stroke; IVW, inverse variance weighted; LAS, large‐artery atherosclerotic stroke; MR, Mendelian randomization; MR‐PRESSO, Mendelian Randomization Pleiotropy Residual Sum and Outlier; MVMR, multivariable Mendelian randomization analysis; SVS, small‐vessel stroke.

The 7 non‐pleiotropic SNPs that are associated with only uric acid or/and gout.

John Wiley & Sons, Ltd

The association estimates of the SNPs with cognitive performance, Alzheimer disease, CHD, MI, SBP, and ischemic stroke and its subtypes are presented in Tables [S5](#jah34339-sup-0001){ref-type="supplementary-material"} through S13, respectively. Figures [S1](#jah34339-sup-0001){ref-type="supplementary-material"} through S9 are Forest plots representing the individual SNP MR estimates of the 28 SNPs for all outcomes, respectively. Funnel and Radial plots to visualize the presence of heterogeneity for every outcome are provided in Figures [S10](#jah34339-sup-0001){ref-type="supplementary-material"} through S18. Forest plots containing the association estimates found using each method for the uric acid‐cognition and uric acid‐Alzheimer disease analyses are provided in Figures [S19 and S20](#jah34339-sup-0001){ref-type="supplementary-material"}, respectively. Similarly, Figure [S21](#jah34339-sup-0001){ref-type="supplementary-material"} is a Forest plot of the uric acid‐CHD and uric acid‐MI relationships, with Figures [S22 and S23](#jah34339-sup-0001){ref-type="supplementary-material"} the same for uric acid‐SBP and uric acid‐ischemic stroke and its subtypes, respectively.

Discussion {#jah34339-sec-0018}
==========

Our study did not provide consistent MR evidence to support a causal effect of genetically determined serum uric acid levels on cognitive function, Alzheimer disease, CHD, MI, or ischemic stroke, including its subtypes (cardioembolic stroke, SVS, and LAS), despite the associations observed in many observational studies.[1](#jah34339-bib-0001){ref-type="ref"}, [2](#jah34339-bib-0002){ref-type="ref"}, [3](#jah34339-bib-0003){ref-type="ref"}, [4](#jah34339-bib-0004){ref-type="ref"}, [5](#jah34339-bib-0005){ref-type="ref"} Although there was some evidence for an association with cognitive function, coronary outcomes and SBP, the findings did not survive correction for multiple testing and sensitivity analyses investigating bias related to pleiotropy. Although the analysis with 7 instrument SNPs had lower statistical power than that with 28 SNPs, it is important to appreciate that all the IVW MR analyses had sufficient power to detect clinically meaningful associations. These results will therefore help interpret results from ongoing clinical trials and inform the direction of future study.

Our results were suggestive of an inverse association between uric acid and cognitive performance, as the effect estimates of this relationship were consistent throughout all analysis methods and approached statistical significance, even after accounting for multiple testing. Whether this effect is of clinical importance, however, needs to be clarified and more research is needed. We also need to acknowledge that this study does not exclude the presence of smaller effects, or effects of allopurinol lowering drugs distinct from the effect of general urate lowering. Any relationship between uric acid levels and cognitive function or dementia is likely to be complex given the heterogeneous nature of dementias, the antioxidant effects of uric acid and the detrimental effects of chronic hyperuricemia on the vasculature. Observational studies suggest the relationship may differ by dementia subtype. In a recent systematic review and meta‐analysis, serum uric acid levels were lower in people with Alzheimer disease and dementia associated with Parkinson disease but there was no association with vascular dementia.[39](#jah34339-bib-0039){ref-type="ref"} Experimental studies suggest a neuroprotective effect of uric acid which may be beneficial in some neurodegenerative disorders,[6](#jah34339-bib-0006){ref-type="ref"} but also that chronic hyperuricemia could induce cognitive impairment via vascular damage.[5](#jah34339-bib-0005){ref-type="ref"} Our data support this. Studies assessing the relationship between instrumental variables for uric acid and vascular dementia would be helpful.

Considering the other outcomes, while for CHD and SBP there was some evidence of an association, the importance and clinical relevance of this is debatable. Our analysis for SBP suggested that 1 mg/dL increase in genetically determined uric acid would increase blood pressure by 0.34 mm Hg (IVW for the 7 SNPs analysis: 95% CI −0.18--0.86; *P*=0.25). However, other MR studies do support a causal role for hyperuricemia in hypertension[10](#jah34339-bib-0010){ref-type="ref"}, [12](#jah34339-bib-0012){ref-type="ref"} (although there are discordant reports[11](#jah34339-bib-0011){ref-type="ref"}, [40](#jah34339-bib-0040){ref-type="ref"}) and clinical trials suggest a larger effect. A clinical trial of uric acid lowering therapies in adolescents showed an ≈10 mm Hg fall in SBP with both allopurinol and probenecid.[41](#jah34339-bib-0041){ref-type="ref"}, [42](#jah34339-bib-0042){ref-type="ref"} If a fall of this magnitude was present in older adults, it would be associated with a 41% reduction in stroke events and a 22% reduction in CHD events.[41](#jah34339-bib-0041){ref-type="ref"}, [42](#jah34339-bib-0042){ref-type="ref"} Whether these changes exist in older adults at risk of cardiovascular disease now needs to be established in clinical trials. The presence of a small effect in an MR study in the predominantly "healthy" UK Biobank population does not exclude a similar larger and important effect of uric acid reduction in hyperuricemia adults at increased risk. Further clinical trials are needed to assess this. The fact that both a xanthine oxidase inhibitor and a uricosuric drug lowered blood pressure in adolescents raises the possibility that this effect is mediated by uric acid itself and not by xanthine oxidase inhibition or a reduction in oxidative stress. However, there are alternative explanations. The effects of xanthine oxidase inhibitors may be uric acid independent; high doses of allopurinol, but not probenecid, improved measures of endothelial function in adults with heart failure and it is of interest that trials of uric acid reduction have been neutral in this setting.[43](#jah34339-bib-0043){ref-type="ref"}, [44](#jah34339-bib-0044){ref-type="ref"} Further, probenecid may exert its effects via changes in renal function and MR studies have suggested that activity of uric acid transporters rather than the level of uric acid itself is related to renal function.[45](#jah34339-bib-0045){ref-type="ref"} Whether the observed effects of probenecid on renal function are because of this mechanism or a uric acid effect is unclear. Further clinical study should aim to establish this.

MR studies have also shown an association between uric acid and CHD[10](#jah34339-bib-0010){ref-type="ref"}, [12](#jah34339-bib-0012){ref-type="ref"} but again there are conflicting reports.[40](#jah34339-bib-0040){ref-type="ref"} Hypertension is the biggest risk factor for stroke and if hyperuricemia causes this, a downstream effect on the risk of stroke would be expected. Stroke is a heterogeneous condition and the presence of an association with CHD makes it attractive to hypothesize there would be an association with LAS, which overlap in its etiology.[26](#jah34339-bib-0026){ref-type="ref"} However, we saw no MR evidence of this.

The findings of this study will help plan and interpret results of clinical trials of uric acid reduction. Both allopurinol and probenecid have been shown to reduce blood pressure in adolescents by between 6 and 10 mm Hg systolic.[41](#jah34339-bib-0041){ref-type="ref"}, [42](#jah34339-bib-0042){ref-type="ref"} Allopurinol has also been shown to reduce left ventricular hypertrophy and carotid intima media thickness.[43](#jah34339-bib-0043){ref-type="ref"}, [46](#jah34339-bib-0046){ref-type="ref"}, [47](#jah34339-bib-0047){ref-type="ref"} Left ventricular hypertrophy is a key risk factor for stroke and the lack of association with stroke (and LAS in particular in our study) raises the possibility that these effects are mediated by xanthine oxidase and not uric acid. Our data do not exclude potentially beneficial effects of allopurinol that are mediated via uric acid independent mechanism. Indeed, if clinical trials of allopurinol yield benefit on outcomes such as stroke, we could infer these effects are uric acid independent. Furthermore, patients with stroke have a higher risk of cognitive impairment and cardiac disease so a potentially beneficial effect of uric acid reduction in this population cannot be excluded. Overall however, we feel our data suggest trials of uric acid reduction in the setting of cardiovascular disease should focus on cardiac end points or blood pressure reduction. It is likely that if clinically important effects are seen that they will at least in part be because of urate independent mechanisms. Further, the potential for genetic information to identify people with particularly harmful forms of hyperuricemia, or who are most likely to respond to uric acid reduction, should be considered. This could be done by analysis of genetic data in ongoing trials.

Strengths of our study include the large sample size for each MR analysis with good statistical power. Both the 28 and 7 SNPs analyses had sufficient power to detect clinically relevant effect estimates (Tables [S3 and S4](#jah34339-sup-0001){ref-type="supplementary-material"}). The availability of large‐scale GWASs for a range of relevant neurological and vascular outcomes further allowed investigation across the relevant outcome phenotypes in a manner more efficient that afforded by clinical trial,[48](#jah34339-bib-0048){ref-type="ref"} and also overcoming the issues of confounding and reverse causation bias that can limit traditional observational research.[49](#jah34339-bib-0049){ref-type="ref"} Furthermore, robust methods were applied to deal with possible violations of the requisite assumptions of MR, including horizontal pleiotropy.[50](#jah34339-bib-0050){ref-type="ref"}

Limitations of this work include the fact that the sample size for subtypes of stroke was smaller than for other analyses, having potential implications for fine‐mapping the effects of uric acid on stroke subtypes that vary in their underlying etiology and pathophysiology.[26](#jah34339-bib-0026){ref-type="ref"} Furthermore, it is important to appreciate that MR measures the cumulative effect of lifelong exposure to genetic variants related to serum uric acid levels, and that this is not the same as studying the effect of a discrete clinical intervention in adult life.[51](#jah34339-bib-0051){ref-type="ref"} These MR results should therefore not be extrapolated to assume the effect of clinical intervention on uric acid levels, particularly as the MR approach may be subject to some residual bias related to pleiotropy despite the pleiotropy robust approaches. Furthermore, therapies for uric acid reduction may be having effects on neurological and vascular disease partly unrelated to their effects on uric acid.[43](#jah34339-bib-0043){ref-type="ref"}, [44](#jah34339-bib-0044){ref-type="ref"}, [45](#jah34339-bib-0045){ref-type="ref"}, [46](#jah34339-bib-0046){ref-type="ref"}, [47](#jah34339-bib-0047){ref-type="ref"} Finally, because of the fact that there is no available power calculation technique for MR‐Egger, we were not able to provide statistical power calculations for this analysis. Therefore, our analysis could contain false negative results on the MR‐Egger test for directional pleiotropy.

Conclusions {#jah34339-sec-0019}
===========

In conclusion, our study did not provide consistent evidence to support that genetically determined serum uric acid has a clinically relevant causal effect on risk of the considered cardiovascular and neurovascular outcomes. If there is an effect of urate lowering drugs on these mechanisms, it may be mediated by urate independent mechanisms.
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